Addition of hyperbaric oxygen therapy versus usual care alone for inflammatory bowel disease: A systematic review and meta-analysis

You, J.-h., Jiang, J.-l., He, W.-b., Ma, H., Zhou, M., Chen, X.-x., Liu, Q.-l. and Huang, C. (2022) Addition of hyperbaric oxygen therapy versus usual care alone for inflammatory bowel disease: A systematic review and meta-analysis. Heliyon, 8(10), e11007. (doi: 10.1016/j.heliyon.2022.e11007) (PMID:36276722) (PMCID:PMC9583108)

Abstract

Objective: Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease that includes ulcerative colitis (UC) and Crohn's disease (CD). Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized environment. Existing literature suggests that HBOT may be an effective therapy for IBD, but a quantitative analysis is lacking. This study aims to estimate the adjunctive role of HBOT in treating IBD and lowering its recurrence rate. Design: Systematic review and meta-analysis. Methods: The Cochrane Library, EMBASE, PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and Wanfang databases were systematically searched by two reviewers independently. Meta-analyses were performed using Review Manager (RevMan, version 5.3). A random-effects model was applied due to the heterogeneity between studies. Results: Twenty-nine out of the initially identified 606 articles were covered in this review, with a total of 2151 patients (2071 for UC and 80 for CD). No randomized data of HBOT for CD were included. Among UC patients, usual care plus HBOT were more likely to achieve a clinical response than usual care alone (risk ratio [RR], 1.24; 95% confidence interval (CI), 1.17 to 1.31; P < 0.001). Subgroup analysis showed that the number of HBOT sessions had no statistically significant effect on overall efficacy (P > 0.05). The pooled data showed a lower recurrence rate in the usual care plus HBOT group (RR, 0.35; 95% CI, 0.24 to 0.53; P < 0.001). The standardized mean difference in the serum tumor necrosis factor level between HBOT and non-HBOT groups was -2.13 (95% CI, -3.09 to -1.18; P < 0.001). No severe adverse events of HBOT were observed. Conclusions: HBOT might be an effective and safe adjunctive treatment for IBD. Further studies are required to investigate the optimal protocol of HBOT in IBD treatment.

• Item Type: Articles
• Additional Information: This work was supported by Key Research and Development project of Sichuan Provincial Science and Technology Department (2018SZ0082) and 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University (2021HXFH063).
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Liu, Qiaoling
• Authors: You, J.-h., Jiang, J.-l., He, W.-b., Ma, H., Zhou, M., Chen, X.-x., Liu, Q.-l., and Huang, C.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Heliyon
• Publisher: Elsevier (Cell Press)
• ISSN: 2405-8440
• ISSN (Online): 2405-8440
• Published Online: 14 October 2022
• Copyright Holders: Copyright © 2022 The Authors
• First Published: First published in Heliyon 8(10):e11007
• Publisher Policy: Reproduced under a Creative Commons license